These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31624633)

  • 1. Quantitative systems toxicology (QST) reproduces species differences in PF-04895162 liver safety due to combined mitochondrial and bile acid toxicity.
    Generaux G; Lakhani VV; Yang Y; Nadanaciva S; Qiu L; Riccardi K; Di L; Howell BA; Siler SQ; Watkins PB; Barton HA; Aleo MD; Shoda LKM
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00523. PubMed ID: 31624633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Systems Toxicology Analysis of In Vitro Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury.
    Longo DM; Woodhead JL; Walker P; Herédi-Szabó K; Mogyorósi K; Wolenski FS; Dragan YP; Mosedale M; Siler SQ; Watkins PB; Howell BA
    Toxicol Sci; 2019 Feb; 167(2):458-467. PubMed ID: 30289550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Two-Tiered In Vitro Approach to De-Risk Drug Candidates for Potential Bile Salt Export Pump Inhibition Liabilities in Drug Discovery.
    Hafey MJ; Houle R; Tanis KQ; Knemeyer I; Shang J; Chen Q; Baudy A; Monroe J; Sistare FD; Evers R
    Drug Metab Dispos; 2020 Nov; 48(11):1147-1160. PubMed ID: 32943412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of PF‐04895162, a Kv7 channel opener, reveals unexpected hepatotoxicity in healthy subjects, but not rats or monkeys: clinical evidence of disrupted bile acid homeostasis.
    Aleo MD; Aubrecht J; D Bonin P; Burt DA; Colangelo J; Luo L; Schomaker S; Swiss R; Kirby S; C Rigdon G; Dua P
    Pharmacol Res Perspect; 2019 Feb; 7(1):e00467. PubMed ID: 30784208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a Bile Salt Export Pump Knockdown Rat Susceptibility Model to Interrogate Mechanism of Drug-Induced Liver Toxicity.
    Li Y; Evers R; Hafey MJ; Cheon K; Duong H; Lynch D; LaFranco-Scheuch L; Pacchione S; Tamburino AM; Tanis KQ; Geddes K; Holder D; Zhang NR; Kang W; Gonzalez RJ; Galijatovic-Idrizbegovic A; Pearson KM; Lebron JA; Glaab WE; Sistare FD
    Toxicol Sci; 2019 Jul; 170(1):180-198. PubMed ID: 30903168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental Evidence of Liver Injury by BSEP-Inhibiting Drugs With a Bile Salt Supplementation in Rats.
    Yang F; Takeuchi T; Tsuneyama K; Yokoi T; Oda S
    Toxicol Sci; 2019 Jul; 170(1):95-108. PubMed ID: 30985903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Morgan RE; van Staden CJ; Chen Y; Kalyanaraman N; Kalanzi J; Dunn RT; Afshari CA; Hamadeh HK
    Toxicol Sci; 2013 Nov; 136(1):216-41. PubMed ID: 23956101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Species differences in hepatobiliary disposition of taurocholic acid in human and rat sandwich-cultured hepatocytes: implications for drug-induced liver injury.
    Yang K; Pfeifer ND; Köck K; Brouwer KL
    J Pharmacol Exp Ther; 2015 May; 353(2):415-23. PubMed ID: 25711339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human.
    Jemnitz K; Veres Z; Vereczkey L
    Toxicol Sci; 2010 May; 115(1):80-8. PubMed ID: 20147439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Morgan RE; Trauner M; van Staden CJ; Lee PH; Ramachandran B; Eschenberg M; Afshari CA; Qualls CW; Lightfoot-Dunn R; Hamadeh HK
    Toxicol Sci; 2010 Dec; 118(2):485-500. PubMed ID: 20829430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective.
    Kenna JG; Taskar KS; Battista C; Bourdet DL; Brouwer KLR; Brouwer KR; Dai D; Funk C; Hafey MJ; Lai Y; Maher J; Pak YA; Pedersen JM; Polli JW; Rodrigues AD; Watkins PB; Yang K; Yucha RW;
    Clin Pharmacol Ther; 2018 Nov; 104(5):916-932. PubMed ID: 30137645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity.
    Yang K; Woodhead JL; Watkins PB; Howell BA; Brouwer KL
    Clin Pharmacol Ther; 2014 Nov; 96(5):589-98. PubMed ID: 25068506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters.
    Sissung TM; Huang PA; Hauke RJ; McCrea EM; Peer CJ; Barbier RH; Strope JD; Ley AM; Zhang M; Hong JA; Venzon D; Jackson JP; Brouwer KR; Grohar P; Glod J; Widemann BC; Heller T; Schrump DS; Figg WD
    Mol Pharmacol; 2019 Aug; 96(2):158-167. PubMed ID: 31175181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of bile salt transport by drugs associated with liver injury in primary hepatocytes from human, monkey, dog, rat, and mouse.
    Zhang J; He K; Cai L; Chen YC; Yang Y; Shi Q; Woolf TF; Ge W; Guo L; Borlak J; Tong W
    Chem Biol Interact; 2016 Aug; 255():45-54. PubMed ID: 27000539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Systems Toxicology Identifies Independent Mechanisms for Hepatotoxicity and Bilirubin Elevations Due to AKR1C3 Inhibitor BAY1128688.
    Battista C; Shoda LKM; Watkins PB; Groettrup-Wolfers E; Rottmann A; Raschke M; Generaux GT
    Clin Pharmacol Ther; 2023 Nov; 114(5):1023-1032. PubMed ID: 37501650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The C-DILI™ Assay: An Integrated In Vitro Approach to Predict Cholestatic Hepatotoxicity.
    Jackson JP; Brouwer KR
    Methods Mol Biol; 2019; 1981():75-85. PubMed ID: 31016648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro model systems to investigate bile salt export pump (BSEP) activity and drug interactions: A review.
    Cheng Y; Woolf TF; Gan J; He K
    Chem Biol Interact; 2016 Aug; 255():23-30. PubMed ID: 26683212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.
    Fattinger K; Funk C; Pantze M; Weber C; Reichen J; Stieger B; Meier PJ
    Clin Pharmacol Ther; 2001 Apr; 69(4):223-31. PubMed ID: 11309550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology Modeling.
    Woodhead JL; Yang K; Oldach D; MacLauchlin C; Fernandes P; Watkins PB; Siler SQ; Howell BA
    Pharm Res; 2019 Feb; 36(3):48. PubMed ID: 30734107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Bile Acid-Dependent Mechanisms of Hepatotoxicity Associated with Tyrosine Kinase Inhibitors.
    Saran C; Sundqvist L; Ho H; Niskanen J; Honkakoski P; Brouwer KLR
    J Pharmacol Exp Ther; 2022 Feb; 380(2):114-125. PubMed ID: 34794962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.